KeRun Biopharmaceutical R&D Co., Ltd (KeRun) is an innovative platform enterprise dedicated to the development of recombinant protein drugs for therapeutic purposes. Since its establishment, it has been guided by clinical needs and has been committed to providing patients with high-quality, accessible, and comprehensive treatment plans.

KeRun has been focusing on prokaryotic and yeast expression systems for 20 years, and has established domestically leading biopharmaceutical research and development technology platforms with independent intellectual property rights, including industrial large-scale inclusion body refolding, nanobody expression preparation, and long-acting drugs of albumin nanobody fusion protein. In 2010, the yeast pilot scale-up technology platform was granted significant special support from the national "Eleventh Five-Year Plan," signifying that this technology is at the forefront in China. The establishment of multiple core technology platforms has provided a continuous impetus for the development of products with competitive advantages and commercial potential.

KeRun's technological prowess, stemming from its proprietary platform, coupled with its commitment to a distinctive product development strategy, has led to the successful development of two new domestically launched drugs. Among these is an innovative biological class I new drug, unique within the oncology field, for which phase II/III combined clinical trials are currently underway. In addition, a pioneering therapeutic ophthalmic product with promising potential is in the midst of Phase I clinical research. Furthermore, two independently developed biopharmaceuticals have completed the technology transfer process, nearing industrialization. Concurrently, KeRun has undergone an innovation transformation, venturing into a collaborative model for new drug development, and has seen initial success. In the realm of innovative drug development, three best-in-class new drugs are in an accelerated research and development phase, with significant breakthroughs achieved in proof-of-concept.Furthermore, the company has embraced numerous pivotal national endeavors, encompassing the prestigious National 'Eleventh Five-Year Plan' aimed at groundbreaking new drug development, noteworthy major special projects sponsored by the National Development and Reform Commission, as well as the prestigious National Science and Technology Innovation Fund.

Dr. Li Shugang, the visionary founder of KeRun, has steadfastly guided the company onto a robust growth trajectory, fueled by his profound grasp of the evolutionary principles and competitive landscape of the biopharmaceutical industry. His distinguished reputation within the biopharmaceutical sphere has garnered exclusive interview opportunities and coverage in prestigious publications such as "China Pharmaceutical Technology Economy and Management" and "Scientific Chinese." Adhering resolutely to the credo of "unity and openness," Dr. Li has meticulously crafted a professional, high-performing, and cohesive R&D team, thereby laying a solid foundation for KeRun's enduring success. Boasting a seasoned core of over a decade's expertise in novel drug discovery, the company's key personnel constitute a well-balanced talent pool. Furthermore, KeRun has rallied an elite advisory panel, spearheaded by top-tier international Chinese scientists who bring a global perspective to the table. This expert consortium encompasses expertise across drug molecular design, manufacturing processes, pharmacology, toxicology, clinical practice, regulatory affairs, and commercialization, empowering KeRun's transformative innovation journey and catalyzing its dynamic growth.Driven by its influence in the industry, professional magazines such as "China Pharmaceutical Technology, Economy and Management" and "Scientific Chinese" have successively conducted exclusive interviews with Dr. Li.

In the future, KeRun will steadfastly uphold the development philosophy of win-win cooperation, capitalize on its own strengths, actively pursue deep complementary cooperation with outstanding domestic and foreign enterprises, and strive to establish KeRun as a first-class domestic biopharmaceutical enterprise primarily focusing on ophthalmic drugs.